The Annual Clinical Trials Roundup
2024 Edition

Our latest Clinical Trials Roundup focuses on Phase I–III clinical trials initiated in 2023 across all therapeutic areas covered by Trialtrove. This annual report includes in-depth analyses of key diseases, sponsoring companies, and geographies that impact the pharma industry, as well as a look at what’s ahead so you can elevate your clinical trials strategy.


Phase I-III clinical trial activity by volume and growth, 2017-23 Year of trial initiation 2017 2018 2019 2020 2021 2022 2023 Trial count 9,959 9,104 10,410 9,819 7,765 7,606 6,794 Year-over-year growth 9.4% -12.5% 6% 26% 2% 12% 12% Year-over-year growth (excluding COVID-19 trials) 13% -6% 22% -4% 2% 12% 12% Trial count (excluding COVID-19 trials) 6,794 9,654 8,541 9,077 7,424 7,765 7,606

Source: Trialtrove, June 2024

This infographic gives you a sampling of top-line findings from the annual Clinical Trials Roundup 2024 Edition, as well as a snapshot of the trends that drove 2023’s rebound in trial starts.

''

Rankings of top 10 industry trial sponsors for 2023

Sponsor Rank 2023 (2022) # of trials 2023 (2022) AstraZeneca Pfizer Merck & Co. Roche Jiangsu Hengrui Pharmaceuticals Bristol-Myers Squibb Eli Lilly Sino Biopharmaceutical Novartis Johnson & Johnson 1 (2) 2 (4) 3 (1) 3 (3) 5 (5) 6 (8) 7 (9) 8 (11) 9 (6) 10 (7) 139 (122) 128 (112) 126 (148) 126 (114) 120 (106) 98 (84) 95 (79) 85 (61) 74 (92) 66 (85)

Source: Trialtrove, June 2024



The Annual Clinical Trials Roundup 2024 Edition, powered by Trialtrove, offers multilayered insights into 2023’s recovery in trial starts and how trial initiations break down among companies, therapeutic, and geographic areas.

''

Exploring the Asia-Pacific Clinical Trials Landscape: Asking the Five W’s

The Asia-Pacific (APAC) region has emerged as a hub for global clinical trials in recent years. Since 2021, APAC has outpaced the rest of the world (RoW) in terms of clinical trial starts, making this a key region of focus for clinical planning.


Number of Phase I–IV trials starts in APAC by trial locations, percentage of APAC trials, and CAGR, 2019–23

2020 4,646 716 745 908 834 875 2022 4,854 607 769 746 819 752 % in APAC 62% 11% 10% 10% 9% 8% CAGR 8% -5% -4% -4% -1% -1% Start year China Japan South Korea India Australia Rest of APAC 2019 3,766 909 735 614 674 641 2021 5,701 780 868 939 996 1,000 2023 5,486 510 636 580 603 703

Source: Trialtrove, August 2024


This infographic gives highlights from the white paper, “Exploring the Asia-Pacific Clinical Trials Landscape: Asking the Five W’s,” which presents Trialtrove-curated information on trial starts in the APAC region.

''

Number and percentage of Phase I–IV trials starting in APAC/RoW, 2019–23

12,000 10,000  8,000  6,000  4,000  2,000         0 60% 50% 40% 30% 20% 10% 0% 2019 2020 2021 2022 2023 Trial start year Trial count Percentages of trials in APAC APAC APAC % RoW

Source: Trialtrove, August 2024


Our white paper, “Exploring the Asia-Pacific Clinical Trials Landscape: Asking the Five W’s,” takes a detailed look at clinical trial initiations in the APAC region, as well as the top countries and therapeutic areas within its borders.

''
Trialtrove: the tool behind the data

Meet Trialtrove, the engine driving these reports. This powerful solution delivers world-class data to help you design and run more cost-effective clinical trials with better outcomes and less risk. With Trialtrove, you can optimize your protocol design, anticipate competitive threats to your programs, and use feasibility and trial timing analysis to inform your country selection.

''
Book a demo

Book a meeting today to explore how Trialtrove can help.


Citeline may contact you about relevant products, services and content. To opt out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Thank you for your interest in Citeline. Your message has been submitted and our team will be in touch soon.